United States of America v. St. Mark's Hospital

District Court, D. Utah·Decided June 17, 2020·No. 2:16-cv-00304·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF UTAH

UNITED STATES OF AMERICA, ex rel. GERALD POLUKOFF, M.D.,

Plaintiff/Relator, MEMORANDUM DECISION AND ORDER DENYING RELATOR’S v. MOTIONS TO EXCLUDE EXPERTS

ST. MARK’S HOSPITAL; INTERMOUNTAIN HEALTHCARE, INC.; INTERMOUNTAIN MEDICAL CENTER; SHERMAN SORENSEN, M.D.; Case No. 2:16-CV-304 TS and SORENSEN CARDIOVASCULAR GROUP, District Judge Ted Stewart

Defendants.

This matter is before the Court on Plaintiff/Relator Gerald Polukoff, M.D.’s (“Relator”) twin motions to exclude testimony of Dr. John Lassetter1 and Dr. Jonathan Tobis2—proposed expert witnesses retained by Sherman Sorensen, M.D. and Sorensen Cardiovascular Group (collectively, “Defendants”). For the reasons discussed below, the Court will deny both motions. I. BACKGROUND This case commenced on December 6, 2012, when Relator filed a qui tam action, alleging that Defendants performed medically unnecessary patent foramen ovale (“PFO”) and/or atrial septal defect (“ASD”) closures, fraudulently collecting payment from the United States Government in violation of the False Claims Act, 31 U.S.C. §§ 3729–32.3 Both parties retained

1 Docket No. 380. 2 Docket No. 383. 3 See Docket Nos. 1, 90. experts to opine on the initial subject of discovery, namely the “Standard of Care/Medical Necessity of PFO/ASD Closures in the Medical Community.”4 On December 30, 2019, Relator filed a Motion to Exclude Testimony of Defendants’ Expert Dr. John Lassetter5 and a Motion to Exclude the Testimony and Opinions of Defendants’ Expert Jonathan M. Tobis, M.D.6 Defendants filed their oppositions to both motions on January

13, 2020,7 and Relator filed replies to both on January 27, 2020.8 II. STANDARD OF REVIEW Concerning the admissibility of expert opinion, Federal Rule of Evidence 702 states that: A witness who is qualified as an expert by knowledge, skill, experience, training, or education may testify in the form of an opinion or otherwise if: (a) the expert’s scientific, technical, or other specialized knowledge will help the trier of fact to understand the evidence or to determine a fact in issue; (b) the testimony is based on sufficient facts or data; (c) the testimony is the product of reliable principles and methods; and (d) the expert has reliably applied the principles and methods to the facts of the case.9

4 See Docket No. 262, at 3. 5 Docket No. 380. 6 Docket No. 383. 7 Docket Nos. 395, 396. 8 Docket Nos. 405, 406. 9 FED. R. EVID. 702. Although the standard under Rule 702 is “liberal . . . regarding expert qualifications,”10 “[t]he proponent of expert testimony bears the burden of showing that the testimony is admissible.”11 Rule 702 “imposes upon the trial judge an important ‘gate-keeping’ function with regard to the admissibility of expert opinions.”12 This involves a two-step analysis.13 The district court

“must first determine whether the expert is qualified ‘by knowledge, skill, experience, training, or education’ to render an opinion.”14 Preliminary questions concerning the qualification of a person to be a witness should be established by a preponderance of proof.15 Second, “the court must determine whether the expert’s opinion is reliable by assessing the underlying reasoning and methodology, as set forth in Daubert.”16 “Under Rule 702, a district court must satisfy itself that the proposed expert testimony is both reliable and relevant, in that it will assist the trier of fact, before permitting a jury to assess such testimony.”17 However, “[a]t the Rule 702 gatekeeping stage, district courts must avoid weighing the credibility or persuasiveness of the competing experts’ ultimate conclusions.”18

10 Fowers Fruit Ranch, LLC v. Bio Tech Nutrients, LLC, No. 2:11-CV-105-TC, 2015 WL 2201715, at *1 (D. Utah May 11, 2015) (quoting United States v. Gomez, 67 F.3d 1515, 1526 (10th Cir. 1995)). 11 Id. (quoting Conroy v. Vilsack, 707 F.3d 1163, 1168 (10th Cir. 2013)) (alteration in original). 12 Mathis v. Huff & Puff Trucking, Inc., 787 F.3d 1297, 1307 (10th Cir. 2015) (quoting Ralston v. Smith & Nephew Richards Inc., 275 F.3d 965, 969 (10th Cir. 2001)); see generally Daubert v. Merrell Dow Pharm. Inc., 509 U.S. 579 (1993). 13 See United States v. Nacchio, 555 F.3d 1234, 1241 (10th Cir. 2009) (en banc). 14 Id. (quoting FED. R. EVID. 702). 15 Daubert, 509 U.S. at 592 n.10. 16 Nacchio, 555 F.3d at 1241 (citing United States v. Rodriguez–Felix, 450 F. 3d 1117, 1123 (10th Cir. 2006)). 17 Rodriguez–Felix, 450 F. 3d at 1122–23 (citing FED. R. EVID. 702). 18 Heer v. Costco Wholesale Corp., 589 F. App’x. 854, 862 (10th Cir. 2014) (internal citations omitted). III. DISCUSSION A. Dr. John Lassetter Relator argues Dr. Lassetter should be excluded because he is both unqualified and his testimony is unreliable under Rule 702.19 Each argument is addressed in turn below.

1. Qualifications Whether Dr. Lassetter is qualified to testify “by knowledge, skill, experience, training, or education’ to render an opinion” is the first prong of the court’s Rule 702 gatekeeping analysis.20 Dr. Lasseter’s curriculum vitae shows extensive experience and scholarship in cardiology.21 His expert report reveals he has treated many patients with congenital heart defects, including performing some 30 to 40 PFO/ASD closures per year for over a decade.22 Given his ample experience and training, the Court finds that Dr. Lassetter is qualified to testify as an expert of cardiology. However, parts of Dr. Lassetter’s opinion may be ripe for challenge, and Relator is free to address them on cross-examination. For example, Relator may confront Dr. Lassetter’s

conclusions that fall beyond his expertise. Dr. Lassetter’s expert report states that he was retained “to evaluate and render [his] opinion in regard to whether the closure of patent foramen ovales and/or atrial septal defects for the prevention of stroke meets the government’s definition of ‘reasonable and necessary.’”23 He opines that “Dr. Sorensen met all the criteria set forth by

19 See Docket No. 380. 20 Nacchio, 555 F.3d at 1241. 21 See Docket No. 396-1, at 37–42. 22 Id. at 2–3. 23 Id. at 2. CMS and the FDA.”24 However, Dr. Lassetter also acknowledges that he is not an expert on the Center for Medicare and Medicaid Services (CMS) or Federal Drug Administration (FDA) definitions relevant to the present litigation.25 Such gaps are best addressed through cross- examination.

2. Reliability Relator argues Dr. Lassetter’s testimony is unreliable for several reasons. Specifically, Relator asserts that Dr. Lasseter fails to identify his methodology,26 his testimony is disconnected from the relevant time period,27 his opinions are sometimes contradictory,28 and he falsely claims his conclusions derive from review of a random sample.29 Regarding methodology, Dr. Lassetter explains he reviewed medical literature concerning stroke, “the guidelines,” and medical records for twenty-five patients.30 Further, he “incorporated [his] education, training, expertise and knowledge gained over 27 years of practicing in the field of cardiovascular medicine.”31 This is sufficient. As this Court has previously found,

Free access — add to your briefcase to read the full text and ask questions with AI

United States of America v. St. Mark's Hospital, (D. Utah 2020).

United States of America v. St. Mark's Hospital (United States of America v. St. Mark's Hospital) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Ralston v. Smith & Nephew Richards, Inc.
275 F.3d 965 (Tenth Circuit, 2001)
United States v. Rodriguez-Felix
450 F.3d 1117 (Tenth Circuit, 2006)
United States v. Lupe Gomez
67 F.3d 1515 (Tenth Circuit, 1995)
Conroy v. Vilsack
707 F.3d 1163 (Tenth Circuit, 2013)
United States v. Nacchio
555 F.3d 1234 (Tenth Circuit, 2009)
Mathis v. Huff & Puff Trucking, Inc.
787 F.3d 1297 (Tenth Circuit, 2015)